172 related articles for article (PubMed ID: 7543819)
1. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
Zhang L; Chang CJ; Bacus SS; Hung MC
Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
Zhang L; Lau YK; Xi L; Hong RL; Kim DS; Chen CF; Hortobagyi GN; Chang C; Hung MC
Oncogene; 1998 Jun; 16(22):2855-63. PubMed ID: 9671406
[TBL] [Abstract][Full Text] [Related]
5. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
6. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.
Hong RL; Spohn WH; Hung MC
Clin Cancer Res; 1999 Jul; 5(7):1884-91. PubMed ID: 10430096
[TBL] [Abstract][Full Text] [Related]
7. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
8. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
9. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells.
Pianetti S; Guo S; Kavanagh KT; Sonenshein GE
Cancer Res; 2002 Feb; 62(3):652-5. PubMed ID: 11830514
[TBL] [Abstract][Full Text] [Related]
10. p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
Wildenhain Y; Pawson T; Blackstein ME; Andrulis IL
Oncogene; 1990 Jun; 5(6):879-83. PubMed ID: 1694290
[TBL] [Abstract][Full Text] [Related]
11. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
Zhu XF; Liu ZC; Xie BF; Cai LL; Yang DJ
Ai Zheng; 2003 Aug; 22(8):790-4. PubMed ID: 12917021
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
13. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
15. Basic science of HER-2/neu: a review.
Hung MC; Lau YK
Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
[TBL] [Abstract][Full Text] [Related]
16. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor.
Chan TC; Chang CJ; Koonchanok NM; Geahlen RL
Biochem Biophys Res Commun; 1993 Jun; 193(3):1152-8. PubMed ID: 7686746
[TBL] [Abstract][Full Text] [Related]
18. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
[TBL] [Abstract][Full Text] [Related]
20. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
Brodowicz T; Kandioler D; Tomek S; Ludwig C; Rudas M; Kunstfeld R; Koestler W; Hejna M; Budinsky A; Wiltschke C; Zielinski CC
Br J Cancer; 2001 Nov; 85(11):1764-70. PubMed ID: 11742500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]